- Home
- ZLAB
ZLAB
Zai Lab Limited
as 05-09-2025 4:00pm EST
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
| Founded: | 2013 | Country: | China |
| Employees: | N/A | City: | SHANGHAI |
| Market Cap: | 3.5B | IPO Year: | 2017 |
| Target Price: | $47.37 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.65 - $39.77 | Next Earning Date: | 05-08-2025 |
| Revenue: | $418,326,000 | Revenue Growth: | 43.72% |
| Revenue Growth (this year): | 44.43% | Revenue Growth (next year): | 48.68% |
Stock Insider Trading Activity of Zai Lab Limited (ZLAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Du Ying | ZLAB | Chairperson & CEO | Apr 3 '25 | Sell | $33.11 | 2,945 | $97,503.06 | 479,851 | |
| Chen Yajing | ZLAB | Chief Financial Officer | Apr 3 '25 | Sell | $33.11 | 924 | $30,591.79 | 27,047 | |
| Smiley Joshua L | ZLAB | See Remarks | Apr 3 '25 | Sell | $33.11 | 3,354 | $111,044.23 | 67,345 | |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Apr 3 '25 | Sell | $33.11 | 1,874 | $62,044.39 | 30,375 | |
| Amado Rafael | ZLAB | See Remarks | Apr 3 '25 | Sell | $33.11 | 3,029 | $100,284.13 | 45,178 | |
| Du Ying | ZLAB | Chairperson & CEO | Apr 1 '25 | Sell | $35.89 | 5,808 | $208,472.35 | 479,851 | |
| Chen Yajing | ZLAB | Chief Financial Officer | Apr 1 '25 | Sell | $35.89 | 5,280 | $189,520.32 | 27,047 | |
| Smiley Joshua L | ZLAB | See Remarks | Apr 1 '25 | Sell | $35.89 | 11,740 | $421,395.56 | 67,345 | |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Apr 1 '25 | Sell | $35.89 | 4,369 | $156,820.89 | 30,375 | |
| Amado Rafael | ZLAB | See Remarks | Apr 1 '25 | Sell | $35.89 | 7,541 | $270,676.65 | 45,178 |
Latest Zai Lab Limited News
ZLAB Breaking Stock News: Dive into ZLAB Ticker-Specific Updates for Smart Investing
GuruFocus.com
14 hours ago
Zai Lab Ltd (ZLAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Zacks
a day ago
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say
MT Newswires
a day ago
Zai Lab's Q1 Loss Narrows, Revenue Rises; 2025 Revenue Guidance Reiterated
Business Wire
a day ago
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
Insider Monkey
4 days ago
Zai Lab Limited (ZLAB): Among the Best Breakout Stocks to Buy According to Analysts
Business Wire
14 days ago
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
Business Wire
16 days ago
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
MT Newswires
18 days ago
Zai Lab's Cancer Drug Application Accepted by Chinese Regulator
Compare ZLAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZLAB Zai Lab Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.